JJJoan Joseph

Joan Joseph

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joan Joseph has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Josep Maria Gatell

    AIDS Research Group, Hospital Clinic/IDIBAPS-HIVACAT, School of Medicine, University of Barcelona, Barcelona, Spain

    4 shared publications
  • Narcís Saubi

    Servicio de Enfermedades Infecciosas, Hospital Clínic, Barcelona, Spain

    4 shared publications
  • Eva Mendez-Arancibia

    AIDS Research Unit; Hospital Clínic/IDIBAPS-HIVACAT; University of Barcelona; Barcelona, Spain

    3 shared publications
  • Jennifer L. Evans

    HIV/AIDS Division at San Francisco General Hospital; University of California—San Francisco; San Francisco, CA USA

    3 shared publications
  • Elisa de Lazzari

    HIV Unit, Infectious Diseases Department, Hospital Clínic de Barcelona Barcelona Spain

    2 shared publications
  • Elías Pezzat

    AIDS Research Unit, Hospital Clínic/IDIBAPS-HIVACAT, University of Barcelona, Calle Villarroel 170, 08036, Barcelona, Spain

    2 shared publications

Latest Publications

  • Open Access

    Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials

    by M. Florencia Etcheverry, Jennifer L. Evans, Emilia Sanchez, Eva Mendez-Arancibia, Mercé Meroño, José M. Gatell, Kimberly Page, Joan Joseph

    The potential for implementation of HIV vaccine trials in hard-to-reach female sex workers in an inner city area of Barcelona, Spain was assessed via a study of HIV risk, willingness to participate and the success of retention strategies. In 130 women, serological HIV status, behavioral risk exposures and willingness to participate in future HIV vaccine trials were recorded every six months using a confidential questionnaire. An enhanced retention (ER) strategy was compared with a control retention (CR) strategy comprising the recording of data on appointment cards. HIV seroincidence and retention rates were estimated. Retention rates after 6 and 12 mo of follow-up in the ER group were 76% and 69% respectively compared with 16% and 13% in the CR group. Among the ER group 97% were willing to participate in HIV vaccine trials at baseline and, after 12 mo of follow-up. Willingness was significantly associated with higher HIV risk exposure, and higher education level. Successfully retaining these cohorts over...


  • Open Access

    Pre-Clinical Development of BCG.HIVACAT, an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG

    by Narcís Saubi, Alice Mbewe-Mvula, Ester Gea-Mallorqui, Maximillian Rosario, Josep Maria Gatell, Tomáš Hanke, Joan Joseph

    In the past, we proposed to develop a heterologous recombinant BCG prime-recombinant modified vaccinia virus Ankara (MVA) boost dual pediatric vaccine platform against transmission of breast milk HIV-1 and Mycobacterium tuberculosis (Mtb). In this study, we assembled an E. coli-mycobacterial shuttle plasmid pJH222.HIVACAT expressing HIV-1 clade A immunogen HIVA. This shuttle vector employs an antibiotic resistance-free mechanism based on Operator-Repressor Titration (ORT) system for plasmid selection and maintenance in E. coli and lysine complementation in mycobacteria. This shuttle plasmid was electroporated into parental lysine auxotroph (safer) strain of BCG to generate vaccine BCG.HIVACAT. All procedures complied with Good Laboratory Practices (GLPs). We demonstrated that the episomal plasmid pJH222.HIVACAT was stable in vivo over a 20-week period, and genetically and phenotypically characterized the BCG.HIVACAT vaccine strain. The BCG.HIVACAT vaccine in combination with MVA.HIVA induced HIV-1- and Mtb-specific interferon γ-producing T-cell responses in newborn and adult BALB/c mice. On the other hand, when adult mice were primed with BCG.HIVACAT and boosted with MVA.HIVA.85A, HIV-1-specific CD8+ T-cells producing IFN-γ, TNF-α, IL-2 and CD107a were induced. To assess the biosafety profile of BCG.HIVACAT-MVA.HIVA regimen, body mass loss of newborn mice was monitored regularly throughout the vaccination experiment and no difference was observed between the vaccinated and naïve groups of animals. Thus, we demonstrated T-cell immunogenicity of a novel, safer, GLP-compatible BCG-vectored vaccine using prototype immunogen HIVA. Second generation immunogens derived from HIV-1 as well as other major pediatric pathogens can be constructed in a similar fashion to prime protective responses soon after birth.


  • HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco

    by M. Florencia Etcheverry, Paula J. Lum, Jennifer L. Evans, Emilia Sanchez, Elisa de Lazzari, Eva Mendez-Arancibia, Ernesto Sierra, José M. Gatell, Kimberly Page, Joan Joseph


  • Open Access

    Newborn Mice Vaccination with BCG.HIVA222+ MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes

    by Narcís Saubi, Eung-Jun Im, Raquel Fernández-Lloris, Olga Gil, Pere-Joan Cardona, Josep Maria Gatell, Tomáš Hanke, Joan Joseph

    We have evaluated the influence of age and immunization routes for induction of HIV-1- andM. tuberculosis-specific immune responses after neonatal (7 days old) and adult (7 weeks old) BALB/c mice immunization with BCG.HIVA222prime and MVA.HIVA boost. The specific HIV-1 cellular immune responses were analyzed in spleen cells. The body weight of the newborn mice was weekly recorded. The frequencies of HIV-specific CD8+T cells producing IFN-γ were higher in adult mice vaccinated intradermally and lower in adult and newborn mice vaccinated subcutaneously. In all cases the IFN-γ production was significantly higher when mice were primed with BCG.HIVA222compared with BCGwt. When the HIV-specific CTL activity was assessed, the frequencies of specific killing were higher in newborn mice than in adults. The prime-boost vaccination regimen which includes BCG.HIVA222and MVA.HIVA was safe when inoculated to newborn mice. The administration of BCG.HIVA222to newborn mice is safe and immunogenic and increased the HIV-specific responses induced by MVA.HIVA vaccine. It might be a good model for infant HIV and Tuberculosis bivalent vaccine.


  • Open Access

    Molecular Characterization of Heterologous HIV-1gp120 Gene Expression Disruption inMycobacterium bovisBCG Host Strain: A Critical Issue for Engineering Mycobacterial Based-Vaccine Vectors

    by Joan Joseph, Raquel Fernández-Lloris, Elías Pezzat, Narcís Saubi, Pere-Joan Cardona, Beatriz Mothe, Josep Maria Gatell

    Mycobacterium bovisBacillus Calmette-Guérin (BCG) as a live vector of recombinant bacterial vaccine is a promising system to be used. In this study, we evaluate the disrupted expression of heterologous HIV-1gp120 gene in BCG Pasteur host strain using replicative vectors pMV261 and pJH222. pJH222 carries a lysine complementing gene in BCG lysine auxotrophs. The HIV-1 gp120 gene expression was regulated by BCG hsp60 promoter (in plasmid pMV261) andMycobacteriaspp.α-antigen promoter (in plasmid pJH222). Among 14 rBCG:HIV-1gp120 (pMV261) colonies screened, 12 showed a partial deletion and two showed a complete deletion. However, deletion was not observed in all 10 rBCG:HIV-1gp120 (pJH222) colonies screened. In this study, we demonstrated thatE. coli/Mycobacterial expression vectors bearing a weak promoter and lysine complementing gene in a recombinant lysine auxotroph of BCG could prevent genetic rearrangements and disruption of HIV 1gp120 gene expression, a key issue for engineering Mycobacterial based vaccine vectors.


  • Pilot Study Assessing HIV Vaccine Trial Readiness Among Female Sex Workers, Injection and Non-injection Drug Users, and Men Who Have Sex with Men in Spain

    by María Florencia Etcheverry, Elisa de Lazzari, Jonathan D. Fuchs, Mercé Meroño, Ernesto Sierra, Jorge Del Romero, Jennifer L. Evans, Eva Mendez-Arancibia, Constanza Jacques, Daniela Rojas, et al.

    The purpose of this study was to assess HIV risk and willingness to participate in HIV vaccine trials in three high risk populations in Spain. Eight hundred and forty-four participants, comprising female sex workers, injection and non-injection drug users (IDUs and NIDUs, respectively), and men who have sex with men were tested for HIV and surveyed for risk and willingness to participate in future preventive HIV vaccine trials. HIV seroprevalence was 3.8% (95% CI: 2–11). HIV infection was associated with transgender identification, IDU in the past year, and sex with an IDU or other drug-using partner. The majority (82%) expressed their willingness to participate in HIV vaccine trials. Substantial sexual and parenteral risk in all groups and concomitant willingness to participate in vaccine trials was found, particularly among women and IDUs. Additional longitudinal cohort studies in Spain are needed to plan future vaccine efficacy trials.


  • Progress towards an HIV vaccine based on recombinant Bacillus Calmette–Guérin: failures and challenges

    by Joan Joseph, Narcís Saubi, Elías Pezzat, Josep Maria Gatell

    The need for an affordable, safe and effective HIV vaccine has never been greater. As the immunogenicity of all the vaccine vectors being evaluated currently in human populations is limited, novel vaccine strategies are needed to stimulate the innate immune system, to generate high levels of neutralizing antibodies and to induce strong cell-mediated and mucosal immunity. There is strong evidence for a role for cytotoxic T lymphocytes in the containment of HIV replication. Several vaccine approaches have been tested to elicit anti-HIV cytotoxic T-lymphocyte responses. One promising approach is Bacillus Calmette-Guérin (BCG) as a bacterial live recombinant vaccine vehicle. BCG has a long record of safety in humans and is able to induce long-lasting immunity. In this review, we describe the limitations and challenges of developing a recombinant BCG-based HIV vaccine. We also emphasize possible approaches for overcoming the plasmid instability in vivo and the low levels of gene expression and immunogenicity induction. Today, projects all over the world are focused on the development of an AIDS vaccine. Overcoming the remaining scientific, logistical and financial hurdles to the development of an effective HIV vaccine will require real imagination and firm commitment from all stakeholders.


    • 24 November 2005
      • Vol. 7  (3) , 131-8

    A safe, effective and affordable HIV vaccine--an urgent global need.

    by Joan Joseph, Florencia Etcheverry, José Alcami, Gatell José María

    The need for a safe, effective and affordable HIV vaccine has never been greater. In 2004 almost five million people became infected with HIV. In addition, providing access to antiretrovirals in Africa remains a huge challenge. A successful vaccine against HIV will probably need to stimulate the innate immune system, generate high levels of neutralizing antibodies, induce strong cellular immune responses and mucosal immunity, and should induce broad-spectrum immunity able to cover all HIV subtypes. In this review, we describe the limitations and challenges of developing a safe and effective HIV vaccine. We also emphasize possible approaches for overcoming immune escape in HIV infection, the lessons learned from the clinical trials of HIV-1 candidate vaccines, and the most important scientific highlights of the Keystone 2005 Symposium. When an effective vaccine is eventually found, we will face the enormous task of making it accessible to those who need it most.